FY2025 EPS Forecast for LENZ Therapeutics Boosted by Analyst

Key Points

• HC Wainwright raised its FY2025 earnings per share estimate for LENZ Therapeutics from ($2.84) to ($2.83), maintaining a "Buy" rating with a price target of $48.00.
• LENZ Therapeutics has recently seen interest from institutional investors, with a notable increase in ownership, now totaling 54.32% of the company's stock.
• The company's product candidates, LNZ100 and LNZ101, are currently undergoing Phase III clinical trials aimed at treating presbyopia.

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - HC Wainwright increased their FY2025 earnings estimates for shares of LENZ Therapeutics in a report released on Monday, July 28th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($2.83) per share for the year, up from their previous estimate of ($2.84). HC Wainwright has a "Buy" rating and a $48.00 price objective on the stock. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($0.83) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $1.06 EPS and FY2029 earnings at $2.18 EPS.

Several other brokerages have also commented on LENZ. Raymond James Financial upped their price target on shares of LENZ Therapeutics from $39.00 to $40.00 and gave the stock an "outperform" rating in a research report on Thursday. Citigroup upped their price target on LENZ Therapeutics from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Thursday. Finally, Piper Sandler initiated coverage on LENZ Therapeutics in a research note on Monday, April 14th. They issued an "overweight" rating and a $51.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $49.60.

LENZ Therapeutics Stock Up 0.6%

Shares of LENZ traded up $0.19 during mid-day trading on Wednesday, hitting $29.96. The company had a trading volume of 1,569,366 shares, compared to its average volume of 278,602. LENZ Therapeutics has a 1-year low of $16.53 and a 1-year high of $38.93. The business's 50-day simple moving average is $30.99 and its 200-day simple moving average is $26.90. The stock has a market cap of $854.46 million, a PE ratio of -15.77 and a beta of 0.42.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.05. The business had revenue of $5.00 million during the quarter, compared to analyst estimates of $5.00 million.

Institutional Investors Weigh In On LENZ Therapeutics

A number of large investors have recently added to or reduced their stakes in LENZ. Paradigm Biocapital Advisors LP acquired a new stake in shares of LENZ Therapeutics during the fourth quarter valued at about $22,243,000. Adage Capital Partners GP L.L.C. acquired a new position in LENZ Therapeutics in the first quarter worth about $13,825,000. Price T Rowe Associates Inc. MD increased its holdings in LENZ Therapeutics by 83.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company's stock valued at $23,760,000 after buying an additional 374,326 shares during the last quarter. Granahan Investment Management LLC raised its stake in LENZ Therapeutics by 239.8% during the first quarter. Granahan Investment Management LLC now owns 176,166 shares of the company's stock valued at $4,529,000 after buying an additional 124,324 shares in the last quarter. Finally, Scoggin Management LP bought a new position in LENZ Therapeutics during the 1st quarter worth approximately $2,571,000. 54.32% of the stock is owned by institutional investors and hedge funds.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.